Published article: Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.

Featured Product
Published article: Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.
Home » Featured Product » Published article: Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.

In collaboration, Grifols and Access Biologicals have published “Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.”

Abstract

Seroconversion panels are an important tool for investigating antibody responses and developing serological assays. A seroconversion panel was generated from a single SARS-CoV-2 positive plasma donor over 87 days. This seroconversion panel was tested against 6 SARS-CoV-2 antibody tests (IgG, IgM, and total Ig). All test kits utilized recombinant antigens that are specific to SARS-CoV-2. The seroconversion panel showed IgG responses for SARS-CoV-2 after day 50. IgM levels peaked on day 50 (prior to IgG) and declined in subsequent samples. This seroconversion panel is a useful tool for validation of SARS-CoV-2 antibody assays.

 

View the article on ScienceDirect

 

Related Posts

  • Science,,Medicine,And,Epidemic,Concept,-,Scientists,Wearing,Goggles,And
    Seroconversion panels demonstrate anti-SARS-CoV-2…     07/07/2021 Abstract Seroconversion panels are an important tool for investigating antibody responses in acute and chronic phases of disease and development of serological assays for viral diseases including COVID-19. Globally it is anticipated that vaccines against SARS-CoV-2 will facilitate control of the current pandemic. The two COVID-19 seroconversion panels analyzed in this study were obtained from consenting donors with samples collected before vaccination with the mRNA-1273 vaccine (Moderna) and after the first and second doses of the vaccine. Panel samples were tested for antibodies to SARS-CoV-2 (IgG). Individual subjects with a positive response for anti-SARS-CoV2 IgG in their pre-vaccination samples showed…
  • covid19 vaccine panels
    Access Biologicals is actively collecting serum and…     11/17/2021 Access Biologicals is actively collecting serum and plasma from patients being vaccinated for COVID-19 COVID-19 J&J, Moderna and Pfizer Vaccine Panels Longitudinal Vaccine Panel  (Moderna) 6 samples per subject Following vaccinated donors pre-vaccine to 6 months post vaccination series completed Sample 1: Pre Vaccine Sample 2: Post 1st dose ​Sample 3: Post 2nd dose Sample 4: 1.5 months post 2nd dose Sample 5: 3.5 months post 2nd dose Sample 6: 6.5 months post 2nd dose • Serum only • 15 donors ​​ 14 Subject Panel (J&J) 3 samples per subject Sample 1: 2 weeks prior to their vaccination Sample 2: 2 weeks post their vaccination Sample 3: 2…
  • Panel boxes 5
    Access Biologicals offers panels for assay…     06/30/2021 Did you know Access Biologicals offers panels for assay development, validation and qualification?! For more information about our products, please visit: Panels, ​​​​COVID-19 Panels & Seroconversion Panels ANA (Antinuclear Antibody) Anti-CCP ((cyclic citrullinated peptide) antibodies in the blood)  APLS (antiphospholipid antibody syndrome) Celiac HSV1 & 2 Interference Panel MMRV (measles, mumps, rubella and varicella) SARS-CoV-2 Crossover panel ToRC Vasculitis Vitamin D COVID-19 Panels Normal, Healthy Serum (87 member) pre-pandemic COVID-19 positive single samples available in serum or K2 EDTA COVID-19 Seroconversion Panels HAV Seroconversion Panels Custom panels are available. Contact us about your needs and we can customize a panel for you. Many of…
View all news

Access Biologicals is now a Grifols company. Visit the Grifols Bio Supplies website for all your human biological product needs: www.biosuppliesproducts.com

Visit Bio Supplies wesite now!
X